Optimizing Specialty Pharmacy Practice in HER2-Altered Non-Small Cell Lung Cancer: Testing, Treatment, and Access

Program Description

HER2 alterations represent a distinct molecular subset of non-small cell lung cancer (NSCLC). While HER2 protein overexpression occurs in 10% to 15% of cases, HER2 mutations often occur independent of protein levels. Specialty and oncology pharmacists play a critical role in this landscape by ensuring comprehensive biomarker testing is completed, as molecular distinction is central to therapeutic selection from diagnosis to second-line and later sequencing. Recent clinical data and treatment approvals have introduced highly effective targeted therapies for patients with HER2-altered NSCLC. Throughout the program, attendees will follow a patient case to practice prioritizing diagnostic methodologies, identifying gaps in biomarker reports, and aligning results with evidence-based treatment sequencing. Critical considerations for comprehensive toxicity management, focusing on early detection of tyrosine-kinase inhibitor-associated diarrhea and antibody-drug conjugate-related interstitial lung disease, will also be discussed. Upon completion, specialty and oncology pharmacists will be equipped to support the multidisciplinary care team, improving patient adherence and navigating complex access challenges through expert counseling and proactive intervention.

Target audience: Oncology Pharmacist
Type of activity: Application
Release date: May 14, 2026
Expiration date: May 14, 2027
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Differentiate among HER2 mutation subtypes in non-small cell lung cancer (NSCLC) and biomarker testing results to ensure appropriate patient selection for HER2-targeted therapy
• Use current guideline recommendations and emerging clinical trial evidence to determine appropriate HER2-targeted therapy for patients with NSCLC
• Identify specialty pharmacist-driven strategies for monitoring, preventing, and managing adverse effects associated with HER2-targeted therapies in NSCLC
• Apply strategies to navigate access barriers to HER2-targeted therapies in NSCLC

Accreditation

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-26-120-H01-P. The activity is available for CE credit through May 14, 2027.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Kaiwen Wang, PharmD, BCOP , has the following relevant financial relationships with ineligible companies to disclose:

Consultant: Janssen, Pfizer

Marie Sirek, PharmD, BCACP, CPP, has the following relevant financial relationships with ineligible companies to disclose:

Consultant: Corcept, Nuvation Bio, PartnerRx, Pfizer
Speakers Bureau: Pfizer

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Daphne Davis, PharmD, BCOP; Susan Pordon; Kylie Ferrentino; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com

Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms